{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:30:46Z","timestamp":1786768246576,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40257-024-00871-2","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T11:02:45Z","timestamp":1718103765000},"page":"585-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adherence to Hidradenitis Suppurativa Treatment"],"prefix":"10.1007","volume":"25","author":[{"given":"Caitlyn B.","family":"Dagenet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khiem A.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Hekmatjah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9428","authenticated-orcid":false,"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"issue":"1","key":"871_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81(1):91\u2013101. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.068.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"871_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1301.","journal-title":"J Am Acad Dermatol"},{"key":"871_CR3","unstructured":"World Health Organization. Adherence to long-term therapies\u202f: evidence for action. Published online 200 https:\/\/apps.who.int\/iris\/handle\/10665\/42682. Accessed 8 Feb 2023."},{"issue":"1","key":"871_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","volume":"8","author":"M Bergman","year":"2021","unstructured":"Bergman M, Patel P, Chen N, Jing Y, Saffore CD. Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States. Rheumatol Ther. 2021;8(1):109\u201318. https:\/\/doi.org\/10.1007\/s40744-020-00256-x.","journal-title":"Rheumatol Ther."},{"key":"871_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041007","author":"T Montero-Vilchez","year":"2022","unstructured":"Montero-Vilchez T, Cuenca-Barrales C, Rodriguez-Tejero A, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. Switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11041007.","journal-title":"J Clin Med"},{"issue":"2","key":"871_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000228337","volume":"219","author":"HH van der Zee","year":"2009","unstructured":"van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219(2):143\u20137. https:\/\/doi.org\/10.1159\/000228337.","journal-title":"Dermatology"},{"issue":"5","key":"871_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jaad.2018.12.043","volume":"80","author":"L Schneller-Pavelescu","year":"2019","unstructured":"Schneller-Pavelescu L, Vergara-de Caso E, Martorell A, et al. Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes. J Am Acad Dermatol. 2019;80(5):1455\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.043.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"871_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.17423","volume":"180","author":"C Marasca","year":"2019","unstructured":"Marasca C, Masar\u00e0 A, Annunziata MC, Bettoli V, Luciano MA, Fabbrocini G. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side-effects, improving patients\u2019 compliance. Br J Dermatol. 2019;180(4):949. https:\/\/doi.org\/10.1111\/bjd.17423.","journal-title":"Br J Dermatol"},{"issue":"2","key":"871_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000228334","volume":"219","author":"G Gener","year":"2009","unstructured":"Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148\u201354. https:\/\/doi.org\/10.1159\/000228334.","journal-title":"Dermatology"},{"issue":"2","key":"871_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","volume":"70","author":"KS Leslie","year":"2014","unstructured":"Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(2):243\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.044.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"871_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2006.07.027","volume":"56","author":"L Fardet","year":"2007","unstructured":"Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56(4):624\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2006.07.027.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"871_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000515450","volume":"238","author":"A Docampo-Sim\u00f3n","year":"2022","unstructured":"Docampo-Sim\u00f3n A, Beltr\u00e1-Pic\u00f3 I, S\u00e1nchez-Pujol MJ, et al. Topical 15% resorcinol is associated with high treatment satisfaction in patients with mild to moderate hidradenitis suppurativa. Dermatology. 2022;238(1):82\u20135. https:\/\/doi.org\/10.1159\/000515450.","journal-title":"Dermatology"},{"issue":"6","key":"871_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/bjd.21798","volume":"187","author":"B Midgette","year":"2022","unstructured":"Midgette B, Strunk A, Akilov O, et al. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. Br J Dermatol. 2022;187(6):927\u201335. https:\/\/doi.org\/10.1111\/bjd.21798.","journal-title":"Br J Dermatol"},{"issue":"11","key":"871_CR14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/ddg.14886","volume":"20","author":"K Faverio","year":"2022","unstructured":"Faverio K, Peitsch WK, G\u00f6rig T, et al. Patient preferences in hidradenitis suppurativa (APProach-HS): a discrete choice experiment. J Deutsche Derma Gesell. 2022;20(11):1441\u201352. https:\/\/doi.org\/10.1111\/ddg.14886.","journal-title":"J Deutsche Derma Gesell."},{"issue":"1","key":"871_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/09546634.2013.879092","volume":"26","author":"SF Thomsen","year":"2015","unstructured":"Thomsen SF, Sand FL. Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa. J Dermatolog Treat. 2015;26(1):97\u20138. https:\/\/doi.org\/10.3109\/09546634.2013.879092.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"871_CR16","doi-asserted-by":"publisher","first-page":"jphr.2021.2706","DOI":"10.4081\/jphr.2021.2706","volume":"11","author":"F Velluzzi","year":"2022","unstructured":"Velluzzi F, Anedda J, Pisanu S, et al. Mediterranean diet, lifestyle and quality of life in Sardinian patients affected with hidradenitis suppurativa. J Public Health Res. 2022;11(2):jphr.2021.2706. https:\/\/doi.org\/10.4081\/jphr.2021.2706.","journal-title":"J Public Health Res"},{"issue":"1","key":"871_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/nu11010057","volume":"11","author":"L Barrea","year":"2018","unstructured":"Barrea L, Fabbrocini G, Annunziata G, et al. Role of nutrition and adherence to the mediterranean diet in the multidisciplinary approach of hidradenitis suppurativa: evaluation of nutritional status and its association with severity of disease. Nutrients. 2018;11(1):57. https:\/\/doi.org\/10.3390\/nu11010057.","journal-title":"Nutrients"},{"issue":"6","key":"871_CR18","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3390\/nu13061997","volume":"13","author":"L Barrea","year":"2021","unstructured":"Barrea L, Muscogiuri G, Pugliese G, et al. Association of trimethylamine N-oxide (TMAO) with the clinical severity of hidradenitis suppurativa (acne inversa). Nutrients. 2021;13(6):1997. https:\/\/doi.org\/10.3390\/nu13061997.","journal-title":"Nutrients"},{"key":"871_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/nu14030551","author":"I Lorite-Fuentes","year":"2022","unstructured":"Lorite-Fuentes I, Montero-Vilchez T, Arias-Santiago S, Molina-Leyva A. Potential benefits of the Mediterranean diet and physical activity in patients with hidradenitis suppurativa: a cross-sectional study in a Spanish population. Nutrients. 2022. https:\/\/doi.org\/10.3390\/nu14030551.","journal-title":"Nutrients"},{"issue":"13","key":"871_CR20","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2147\/PPA.S215037","volume":"13","author":"D Brixner","year":"2019","unstructured":"Brixner D, Mittal M, Rubin DT, et al. Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population. Patient Prefer Adherence. 2019;13(13):1545\u201356. https:\/\/doi.org\/10.2147\/PPA.S215037.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"871_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.18553\/jmcp.2019.18443","volume":"25","author":"D Brixner","year":"2019","unstructured":"Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770\u20139. https:\/\/doi.org\/10.18553\/jmcp.2019.18443.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"871_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000500827","volume":"235","author":"P Leiphart","year":"2019","unstructured":"Leiphart P, Kitts S, Sciacca KJ. Adherence to over-the-counter antimicrobial washes in hidradenitis suppurativa patients. Dermatology. 2019;235(5):440\u20131. https:\/\/doi.org\/10.1159\/000500827.","journal-title":"Dermatology"},{"issue":"3","key":"871_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijwd.2020.02.006","volume":"6","author":"A Timila Touhouche","year":"2020","unstructured":"Timila Touhouche A, Chaput B, Marie Rouquet R, et al. Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. Int J Women\u2019s Dermatol. 2020;6(3):164\u20138. https:\/\/doi.org\/10.1016\/j.ijwd.2020.02.006.","journal-title":"Int J Women\u2019s Dermatol"},{"issue":"6","key":"871_CR24","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/bjd.18818","volume":"182","author":"N Shukla","year":"2020","unstructured":"Shukla N, Paul M, Halley M, et al. Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event. Br J Dermatol. 2020;182(6):1490\u20132. https:\/\/doi.org\/10.1111\/bjd.18818.","journal-title":"Br J Dermatol"},{"issue":"2","key":"871_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13240","volume":"33","author":"JM Fernandez","year":"2020","unstructured":"Fernandez JM, Madsen S, Krase JM, Shi VY. Classification and mitigation of negative injection experiences with biologic medications. Dermatol Ther. 2020;33(2): e13240. https:\/\/doi.org\/10.1111\/dth.13240.","journal-title":"Dermatol Ther"},{"issue":"3","key":"871_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","volume":"54","author":"J Bluett","year":"2015","unstructured":"Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford). 2015;54(3):494\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keu358.","journal-title":"Rheumatology (Oxford)"},{"key":"871_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/PPA.S101175","volume":"10","author":"A Ganguli","year":"2016","unstructured":"Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711\u201325. https:\/\/doi.org\/10.2147\/PPA.S101175.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"871_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.066","volume":"88","author":"C Marasca","year":"2023","unstructured":"Marasca C, Masar\u00e0 A, Annunziata MC, Fattore D, Fabbrocini G. Comment on \u201cInterruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes.\u201d J Am Acad Dermatol. 2023;88(5): e269. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.066.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"871_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1203475417716117","volume":"21","author":"A Alavi","year":"2017","unstructured":"Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document. J Cutaneous Med Surg. 2017;21(6):513\u201324. https:\/\/doi.org\/10.1177\/1203475417716117.","journal-title":"J Cutaneous Med Surg."}],"updated-by":[{"DOI":"10.1007\/s40257-025-00930-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00871-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00871-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:55:18Z","timestamp":1739523318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00871-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00871-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-025-00930-2","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-025-00930-2","URL":"https:\/\/doi.org\/10.1007\/s40257-025-00930-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"V.Y.S. is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and\/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Genentech, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt\u2019s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab\/cQuell, MYOR, Polyfins Technology, GpSkin, Alumis, Skin Actives Scientific, and the National Eczema Association. J.L.H. is on the board of directors for the Hidradenitis Suppurativa Foundation and has served as a consultant for AbbVie, Aclaris, Boehringer Ingelheim, Incyte, Novartis, and UCB; as a speaker for AbbVie; and as an investigator for Amgen, Boehringer Ingelheim, and Incyte. S.A., C.B.D., E.M., K.A.T., L.T., J.H., and R.M. have no conflicts to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Participate\/Publish"}},{"value":"Available upon request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: S.A., L.T., R.M., K.A.T., J.H., J.L.H., and V.Y.S. Methodology: S.A., E.M., R.M., and V.Y.S. Formal Analysis: S.A., C.D., and E.M. Resources: L.T., K.A.T., J.H., J.L.H., and V.Y.S. Writing- Original Draft: S.A. and C.D. Writing- Review and Editing: C.D. and S.A. Supervision: K.A.T., J.H., J.L.H., and V.Y.S. Project administration: K.A.T., J.H., J.L.H., and V.Y.S. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}